Pharmaceutical Technology

FEBRUARY 15, 2023

In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Immuno-oncology: Leading companies in cancer monoclonal antibody therapy. Immatics is one of the most important players concerning innovation surrounding cancer monoclonal antibody therapy.

Antibody 261

Antibody Immune Response Protein Development 261

Pharmaceutical Technology

JULY 4, 2022

Brii Biosciences (Brii Bio) has exercised an option for the acquisition of exclusive development and marketing rights for Vir Biotechnology’s investigational antibody, VIR-3434, for Hepatitis B in Greater China, under a partnership agreement. The mAb is presently in the Phase II development stage.

Antibody 279

Antibody Genotype Development Licensing 279

Pharmaceutical Technology

JULY 21, 2022

AstraZeneca has signed a deal with the Federal Office of Public Health (FOPH) of Switzerland to deliver over 1,200 doses of antibody therapy, tixagevimab and cilgavimab combination (AZD7442), for Covid-19 prevention and treatment. In May, the company supplied the first doses of the antibody therapy to Swiss hospitals for Covid-19 prevention.

Antibody 264

Antibody Compliance Clinical Trials Clinical Trials 264

Pharmaceutical Technology

JUNE 28, 2022

Astellas Pharma and Sutro Biopharma have entered a global, strategic partnership and licencing agreement to discover and develop new immunostimulatory antibody-drug conjugates (iADCs). An iADC merges an antibody with a small molecule compound that elicits immunogenic cell death, and an immune-activating molecule.

Development 264

Development Antibody Immune Response Production 264

Pharmaceutical Technology

OCTOBER 21, 2022

AbbVie has announced the acquisition of UK-based biotechnology firm DJS Antibodies for nearly $255m in cash at closing. DJS focuses on the discovery and development of antibody therapies that act on difficult-to-drug disease-causing proteins, such as G protein-coupled receptors (GPCRs).

Antibody 217

Antibody Protein Licensing Licensing 217

Pharmaceutical Technology

JANUARY 9, 2023

Eisai and Biogen have received approval for their antibody Leqembi (lecanemab-irmb) , 100mg/mL injection for intravenous use, from the US Food and Drug Administration (FDA) under the Accelerated Approval Pathway to treat Alzheimer’s disease (AD). The regulatory approval is based on the data obtained from the Phase II trial.

FDA Approval 246

FDA Approval Antibody Clinical Trials Clinical Trials 246

Bio Pharma Dive

APRIL 3, 2024

The startup claims to have a more efficient way to develop biologic drugs that treat disease by turning on cellular pathways, rather than blocking them.

Antibody 299

Antibody Drugs Development 299

Pharmaceutical Technology

OCTOBER 10, 2023

The companies will develop multiple monoclonal antibodies against membrane proteins, such as GPCRs and SLC transporters.

Antibody 147

Antibody Development Protein 147

Pharmaceutical Technology

DECEMBER 22, 2023

Ono has signed an agreement with EVQLV to utilise its AI-powered antibody design engine for the development of new antibody drugs.

Antibody 130

Antibody Development Engineer Drugs 130

Pharmaceutical Technology

SEPTEMBER 14, 2023

AbCellera and Incyte have entered a partnership for the discovery and development of therapeutic antibodies in oncology.

Antibody 147

Antibody Development 147

Pharmaceutical Technology

JANUARY 17, 2023

Spain’s Hospital Universitario 12 de Octubre researchers, along with the Josep Carreras Leukaemia Research Institute, have developed a new cell therapy based on STAb cells to treat a type of leukaemia. The Spanish Association Against Cancer (AECC) provided funding for the new STAb therapy development.

Development 276

Development Gene Therapy Antibody Gene 276

Pharmaceutical Technology

OCTOBER 12, 2023

Almirall will license EpimAb’s Fabs-In-Tandem Immunoglobulin (FIT-Ig) platform to develop up to three bispecific antibody targets.

Antibody 147

Antibody Development Licensing Licensing 147

Pharmaceutical Technology

APRIL 14, 2023

Clinical-stage biopharmaceutical company TORL BioTherapeutics has raised $158m in a Series B financing round for advancing the development of new biologics for cancer treatment. TORL BioTherapeutics is a newly formed, US-based company focused on the development of novel antibody-based therapeutics for cancer patients.

Development 264

Development Clinical Trials Clinical Trials Life Science 264

Pharmaceutical Technology

MAY 8, 2023

In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Innovation in Pharmaceuticals: Anti-influenza antibody compositions. However, not all innovations are equal and nor do they follow a constant upward trend.

Antibody 246

Antibody Vaccine Vaccination Dermatology 246

Pharmaceutical Technology

APRIL 9, 2024

The grant will support the preclinical development of the antibody acquired by Basilea from Spexis in January.

Antibody 130

Antibody Development 130

Pharmaceutical Technology

MAY 8, 2023

Ei s ai and Bliss Biopharmaceutical have entered into a joint development agreement for antibody-drug conjugate (ADC), BB-1701, to treat cancers. The collaboration will help in further development of BB-1701 across the world and advance the ADC towards late stage of development.

Development 246

Development Antibody Clinical Trials Clinical Trials 246

Bio Pharma Dive

MAY 7, 2024

The $200 million round is the latest evidence that surging interest in autoimmune disease cell therapies could expand to include developers of bispecific antibodies, too.

Antibody 189

Antibody Development 189

Pharmaceutical Technology

NOVEMBER 22, 2022

Umoja Biopharma has signed a research agreement with IASO Biotherapeutics (IASO Bio) to develop off-the-shelf therapies for haematological malignancies. The post Umoja and IASO partner to develop therapies for haematological malignancies appeared first on Pharmaceutical Technology.

Development 276

Development In-Vivo Engineer Clinical Trials 276

Pharmaceutical Technology

NOVEMBER 12, 2024

A team of researchers from Uppsala University and KTH Royal Institute of Technology in Sweden has developed a new antibody, which could potentially treat various types of cancer.

Antibody 130

Antibody Development Research 130

Pharmaceutical Technology

OCTOBER 25, 2022

Ast ellas Pharma has announced plans to make a strategic investment to back the development of Taysha Gene Therapies’ adeno-associated virus (AAV) development programmes for Rett syndrome and giant axonal neuropathy (GAN). This would allow the companies to boost the development of new therapy options for Rett syndrome and GAN patients.

Gene Therapy 264

Gene Therapy Gene Development Genetics 264

Bio Pharma Dive

DECEMBER 13, 2022

Months after restructuring and trimming its workforce, the company has teamed up with its original investors to form an antibody drug developer called Launchpad Therapeutics.

Development 217

Development Drugs Antibody 217

Pharmaceutical Technology

APRIL 11, 2023

The US government is reportedly investing more than $5bn in a programme to accelerate the development of new Covid-19 vaccines and treatments. The programme is expected to develop long-lasting monoclonal antibodies and expedite the development of vaccines that produce mucosal immunity to reduce transmission and infection risks.

Vaccine 264

Vaccine Vaccination Development Antibody 264

Bio Pharma Dive

OCTOBER 28, 2020

The two Swiss firms will develop protein drugs that are meant to have similar effects as coronavirus antibodies, but would be easier to mass produce.

Development 214

Development Drugs Protein Antibody 214

Pharmaceutical Technology

SEPTEMBER 4, 2024

Pfizer Ignite will support Acepodia in developing its pipeline cancer therapeutic candidates.

Antibody 246

Antibody Development 246

Bio Pharma Dive

MARCH 14, 2024

The funding for the startup, which partnered with Bristol Myers Squibb last year, adds to a surge of recent investments in developers of antibody-drug conjugates.

Antibody 318

Antibody Development Drugs 318

Pharmaceutical Technology

OCTOBER 20, 2023

The company plans to initiate the Phase II trial of anti-IL-6 antibody in atherosclerotic cardiovascular disease in 2024.

Antibody 147

Antibody Development Trials 147

Pharmaceutical Technology

DECEMBER 16, 2022

Previously disrupted by the Covid-19 pandemic, this past year has seen a return of increased efforts and progress in the development of new treatments for tropical diseases. We ourselves took up activities related to developing Covid-19 vaccines,” says Duffy. There was an all-hands-on-deck environment during Covid-19.

Development 264

Development Drugs Vaccine Vaccination 264

Pharmaceutical Technology

APRIL 3, 2023

BioNTech has signed exclusive licence and collaboration agreements with Duality Biologics (DualityBio) for the development of two antibody-drug conjugate (ADC) assets for solid tumours. Once developed, the ADCs will join BioNTech’s existing portfolio of oncology products.

Development 246

Development Sales Antibody Manufacturing 246

Bio Pharma Dive

SEPTEMBER 29, 2020

The world's attention will be on the FDA as it considers initial data from coronavirus vaccine developers. But several other important drugs, including a CAR-T therapy and an Ebola antibody, will also be on the agency's agenda.

FDA Approval 354

FDA Approval Antibody Vaccine Vaccination 354

Bio Pharma Dive

DECEMBER 1, 2020

Working with University of Pennsylvania researcher Jim Wilson, Regeneron aims to develop a nasal spray version of the coronavirus treatment recently cleared by the Food and Drug Administration.

Gene Therapy 287

Gene Therapy Antibody Gene Drugs 287

Pharmaceutical Technology

APRIL 14, 2023

Twist Bioscience has introduced Twist T-cell receptor (TCR) and Twist chimeric antigen receptor (CAR) libraries to facilitate the development of cell therapies. Researchers will now be able to speed up the creation of tailor-made libraries that can help in identifying and developing new cell therapies.

Development 246

Development Gene Therapy Gene Antibody 246

Bio Pharma Dive

MARCH 25, 2024

The agency wants Regeneron to make more progress with a confirmatory trial before clearing odronextamab, a “bispecific” antibody being developed for multiple blood cancers.

Antibody 299

Antibody Drugs Trials Development 299

Bio Pharma Dive

DECEMBER 8, 2022

As the success of drugs like Enhertu catalyzes new investment in antibody-drug conjugates, the California startup is launching with plans to develop more potent versions of the targeted cancer medicines.

Drugs 334

Drugs Antibody Medicine Development 334

Bio Pharma Dive

DECEMBER 15, 2021

Shares in the biotech, which raised nearly $500 million to develop a treatment able to neutralize a wide range of coronavirus variants, plummeted on news of the disappointing laboratory test results.

Antibody 264

Antibody Drugs Development 264

Bio Pharma Dive

JUNE 29, 2023

The yet-to-be-announced deal for the German biotech is the latest move by Lilly to bulk up its oncology business, adding a drug in early development for solid tumors.

Antibody 228

Antibody Drugs Development 228

Bio Pharma Dive

JANUARY 8, 2024

The proposed takeout follows a spate of dealmaking around antibody-drug conjugates, targeted cancer medicines that have lured AbbVie, Pfizer, Merck and Gilead.

Drugs 200

Drugs Development Antibody Medicine 200

Pharmaceutical Technology

DECEMBER 4, 2023

The $247m deal will focus on the use of generative artificial intelligence to develop an antibody therapy for an unnamed cancer.

Antibody 162

Antibody Drugs Development 162